| Size | Price | |
|---|---|---|
| Other Sizes |
| References | |
|---|---|
| Additional Infomation |
4-aminoantipyrine is a pyrazolone, a member of the class of pyrazoles that is antipyrine substituted at C-4 by an amino group. It is a metabolite of aminopyrine and of metamizole. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, an antirheumatic drug, a peripheral nervous system drug, an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, an antipyretic, a drug metabolite and a marine xenobiotic metabolite. It is a primary amino compound and a pyrazolone. It is functionally related to an antipyrine.
A metabolite of AMINOPYRINE with analgesic and anti-inflammatory properties. It is used as a reagent for biochemical reactions producing peroxides or phenols. Ampyrone stimulates LIVER MICROSOMES and is also used to measure extracellular water. See also: Aminopyrine (annotation moved to). |
| Molecular Formula |
C11H13N3O
|
|---|---|
| Molecular Weight |
203.2404
|
| Exact Mass |
203.105
|
| CAS # |
83-07-8
|
| Related CAS # |
Ampyrone-d3;1329792-51-9
|
| PubChem CID |
2151
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
309.0±45.0 °C at 760 mmHg
|
| Melting Point |
105-110 °C(lit.)
|
| Flash Point |
140.7±28.7 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.607
|
| LogP |
-0.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
15
|
| Complexity |
305
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RLFWWDJHLFCNIJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H13N3O/c1-8-10(12)11(15)14(13(8)2)9-6-4-3-5-7-9/h3-7H,12H2,1-2H3
|
| Chemical Name |
4-amino-1,5-dimethyl-2-phenylpyrazol-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~246.01 mM)
H2O : ~50 mg/mL (~246.01 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 150 mg/mL (738.04 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9203 mL | 24.6015 mL | 49.2029 mL | |
| 5 mM | 0.9841 mL | 4.9203 mL | 9.8406 mL | |
| 10 mM | 0.4920 mL | 2.4601 mL | 4.9203 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04621253 | Completed | Drug: Novalgin | Drug-drug Interaction | University Hospital, Basel, Switzerland | 2020-04-29 | Phase 1 |
| NCT05612516 | Completed | Procedure: Assessment of hydrogen peroxide levels in saliva using trays with reservoir. Procedure: Assessment of hydrogen peroxide levels in saliva using trays without reservoir. |
Consumption | Cairo University | 2024-01-10 | Not Applicable |
| NCT06248437 | Completed | Other: innovative nutraceutical-type food product that we designed called HIC1® from coffee mucilage |
Respiratory Function Loss Sarcopenia |
Fundación Cardiovascular de Colombia | 2019-03-30 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
